(Q44230219)

1 December 2017

0 references

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis (English)

1 reference

relapsing-remitting multiple sclerosis

1 December 2017

0 references

0 references

1 reference

2

F Fazekas

1 reference

1 December 2017

Per Soelberg Sørensen

series ordinal

1

object named as

P S Sorensen

1 reference

1 December 2017

M Lee

3

1 reference

1 December 2017

publication date

1 November 2002

1 reference

European Journal of Neurology

1 December 2017

published in

1 reference

1 December 2017

volume

9

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

557-563

1 reference

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00501.X

10.1046/J.1468-1331.2002.00501.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference